1. Hematologic toxicity profile and efficacy of [
- Author
-
Ismaheel O, Lawal, Alfred, Morgenstern, Mariza, Vorster, Otto, Knoesen, Johncy, Mahapane, Khanyisile N, Hlongwa, Letjie C, Maserumule, Honest, Ndlovu, Janet D, Reed, Gbenga O, Popoola, Kgomotso M G, Mokoala, Amanda, Mdlophane, Frank, Bruchertseifer, and Mike M, Sathekge
- Subjects
Male ,Heterocyclic Compounds, 1-Ring ,Prostatic Neoplasms, Castration-Resistant ,Treatment Outcome ,Positron Emission Tomography Computed Tomography ,Humans ,Kidney Diseases ,Dipeptides ,Lutetium ,Prostate-Specific Antigen ,Radiopharmaceuticals ,Thrombocytopenia ,Retrospective Studies - Abstract
Actinium-225-labeled prostate-specific membrane antigen ([We retrospectively reviewed the medical record of patients treated with [A total of 106 patients were included. Skeletal metastasis was in the superscan pattern in 34 patients (32.1%) and multifocal in 72 patients (67.9%). The median treatment cycle was 4 (range = 1-9). Ninety-eight patients (92.5%) had abnormal baseline hematologic parameters. One patient had grade 4 thrombocytopenia. Grade 3 anemia, leukopenia, and thrombocytopenia were seen in 1 (0.9%), 3 (2.8%), and 2 (1.9%) patients, respectively. Age, the number of treatment cycles, and the presence of renal dysfunction were significant predictors of hematologic toxicity. Eighty-five patients (80.2%) achieved PSA response. The median PFS and OS of the study population were 14:00 (95%CI: 8.15-19.86) months and 15.0 (95%CI: 12.8-17.2) months, respectively.[
- Published
- 2022